FDA Approves GSK Antiretroviral Drug Dolutegravir

The FDA on Monday approved GlaxoSmithKline’s antiretroviral dolutegravir, an integrase strand transfer inhibitor “that was developed by ViiV Healthcare Ltd., its joint venture with two other drugmakers,” Bloomberg reports (Edney, 8/12). “The pill is taken daily in combination with others and can be prescribed to patients who have never taken therapy before, as well as those that have,” The Hill’s “RegWatch” blog notes (Hattem, 8/12). The drug, known under the brand name Tivicay, “was tested in adults in four clinical trials in combination with other antiretroviral drugs, and in one trial involving children,” according to Reuters (8/12).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.